[go: up one dir, main page]

CN118903564A - Hydroxyapatite composite polyester microsphere and preparation method and application thereof - Google Patents

Hydroxyapatite composite polyester microsphere and preparation method and application thereof Download PDF

Info

Publication number
CN118903564A
CN118903564A CN202411221975.7A CN202411221975A CN118903564A CN 118903564 A CN118903564 A CN 118903564A CN 202411221975 A CN202411221975 A CN 202411221975A CN 118903564 A CN118903564 A CN 118903564A
Authority
CN
China
Prior art keywords
solution
hydroxyapatite
microspheres
composite polyester
hydroxyapatite composite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411221975.7A
Other languages
Chinese (zh)
Inventor
王硕
曹峥
杨隽懿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiaxing Ruiqing Medical Technology Co ltd
Original Assignee
Jiaxing Ruiqing Medical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiaxing Ruiqing Medical Technology Co ltd filed Critical Jiaxing Ruiqing Medical Technology Co ltd
Priority to CN202411221975.7A priority Critical patent/CN118903564A/en
Publication of CN118903564A publication Critical patent/CN118903564A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L27/46Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58Materials at least partially resorbable by the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/60Materials for use in artificial skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/112Phosphorus-containing compounds, e.g. phosphates, phosphonates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412Tissue-regenerating or healing or proliferative agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62Encapsulated active agents, e.g. emulsified droplets
    • A61L2300/622Microcapsules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Composite Materials (AREA)
  • Materials Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

The invention provides a hydroxyapatite composite polyester microsphere, a preparation method and application thereof, and relates to the technical field of biomedical materials, wherein the microsphere comprises 25-95 parts by mass of bioabsorbable polyester and 5-18 parts by mass of hydroxyapatite; the preparation method of the microsphere comprises the following steps: solution 1 of a bioabsorbable polyester in an organic solvent; adding hydroxyapatite into the solution 1 to obtain a solution 2; dissolving an emulsifying agent to obtain a solution 3; dropping the solution 2 into the solution 3 to obtain an emulsified solution; washing and drying to obtain hydroxyapatite composite polyester microspheres; the microspheres can be used to prepare a facial filling wrinkle-removing agent. The microsphere has proper size and clear boundary, can reduce the possibility of generating bad symptoms such as inflammation after filling the skin, and is stable and long-acting. The microsphere prepared by the preparation method provided by the invention has the advantages of proper size, clear boundary and good supporting effect after filling the skin.

Description

一种羟基磷灰石复合聚酯微球及其制备方法和应用A kind of hydroxyapatite composite polyester microsphere and its preparation method and application

技术领域Technical Field

本发明涉及生物医用材料技术领域,具体涉及一种羟基磷灰石复合聚酯微球及其制备方法和应用。The invention relates to the technical field of biomedical materials, and in particular to hydroxyapatite composite polyester microspheres and a preparation method and application thereof.

背景技术Background Art

微球的制备方法多种多样,其中乳化法可将高分子材料制成微球,通过相应的合成途径,多种功能性成分能附着在微球上并通用注射器输送到需要的部位。将微球注射到受损或缺失的组织,其结构能在初期起到支撑或保护的作用,并随着结构的降解,其负载物能起到修复、再生等功能。羟基磷灰石(HA)是与生物机体骨骼及牙齿的成分、结构和性质有相似性的材料,化学式为 Ca10(PO4)6(OH)2,具有精确的化学当量 Ca/P=1.67,与人体骨矿物结构非常相似。因此具有很多特性,如良好的骨质结合性,生物活性,可吸收性和优异的生物相容性。越来越多的研究表明,羟基磷灰石在皮肤等软组织的再生修复中也能起到积极作用。There are many methods for preparing microspheres. Among them, the emulsification method can make polymer materials into microspheres. Through the corresponding synthesis pathway, various functional components can be attached to the microspheres and delivered to the required parts by universal syringes. When the microspheres are injected into damaged or missing tissues, their structure can play a supporting or protective role in the early stage, and as the structure degrades, its load can play a repair and regeneration function. Hydroxyapatite (HA) is a material that is similar to the composition, structure and properties of bones and teeth in biological organisms. Its chemical formula is Ca 10 (PO 4 ) 6 (OH) 2 , with an accurate chemical equivalent Ca/P=1.67, which is very similar to the human bone mineral structure. Therefore, it has many characteristics, such as good bone binding, biological activity, absorbability and excellent biocompatibility. More and more studies have shown that hydroxyapatite can also play a positive role in the regeneration and repair of soft tissues such as skin.

微整形针剂通过向皮下注射微球悬液,起到除皱、塑形、嫩肤、抗衰防衰的作用,用于丰额、丰颊、饱满太阳穴、改善法令纹等。作为骨缺损的填充材料,可以填补骨缺损,支持和稳定骨结构。此外,微球能在其生效的区域起到加快物质运输的作用,有利于该区域的血管生成及神经的修复。传统可注射微球一般主要成分为聚乳酸等聚酯类生物可吸收材料,此类可吸收医用高分子经过多年理论及临床的验证,无毒害、具有较低的免疫原性,生物相容性良好,广泛应用在组织工程以及生物医药等多个领域。然而作为皮肤填充剂,单独的聚乳酸材料具有一定的局限性:微球依靠初期的占位作用,起到刺激皮下蛋白分泌的作用,其功效对尺寸较为敏感。较大尺寸的微球虽然能起到更好的占位效果,但其降解周期过长会刺激细胞形成纤维囊包覆,使得植入物难以完全吸收,导致囊肿等并发症。尺寸较小的微球能够顺利吸收,但起到的刺激作用不佳,同时在体内存续时间短,治疗效果不好。因此,在保证微球初期占位,刺激皮下纤维组织分泌胶原蛋白的同时,调节微球整体的降解周期,是能够显著提高可注射微球使用效果的关键。在用于皮肤填充的聚酯类微球中,羟基磷灰石具有优异的生物活性,能与人体组织主动交互,具有更合适的降解时间,避免产生囊肿等并发症,起到更稳定更长效的填充效果,并减少炎症等不良组织发生的可能性。但是现有技术中的方法制备的羟基磷灰石微球尺寸稳定性差,微球的边界性不清晰,所以在应用到面部填充的过程中支撑效果和降解效果不理想。Micro plastic injections can remove wrinkles, reshape, rejuvenate, and resist aging by injecting microsphere suspension into the subcutaneous tissue. They are used to fill the forehead, cheeks, temples, and improve nasolabial folds. As a filling material for bone defects, it can fill bone defects and support and stabilize bone structure. In addition, microspheres can accelerate the transport of substances in the area where they are effective, which is beneficial to angiogenesis and nerve repair in the area. Traditional injectable microspheres are generally mainly composed of polyester bioabsorbable materials such as polylactic acid. Such absorbable medical polymers have been verified by theory and clinical practice for many years. They are non-toxic, have low immunogenicity, and have good biocompatibility. They are widely used in many fields such as tissue engineering and biomedicine. However, as a skin filler, polylactic acid alone has certain limitations: microspheres rely on the initial space-occupying effect to stimulate the secretion of subcutaneous proteins, and their efficacy is sensitive to size. Although larger microspheres can have a better space-occupying effect, their long degradation cycle will stimulate cells to form fibrous capsules, making it difficult for the implant to be completely absorbed, leading to complications such as cysts. Smaller microspheres can be absorbed smoothly, but they have a poor stimulating effect, a short duration in the body, and poor therapeutic effects. Therefore, while ensuring the initial position of the microspheres and stimulating the secretion of collagen by the subcutaneous fibrous tissue, regulating the overall degradation cycle of the microspheres is the key to significantly improving the use effect of injectable microspheres. Among polyester microspheres used for skin filling, hydroxyapatite has excellent biological activity, can actively interact with human tissue, has a more suitable degradation time, avoids complications such as cysts, has a more stable and long-lasting filling effect, and reduces the possibility of adverse tissues such as inflammation. However, the hydroxyapatite microspheres prepared by the methods in the prior art have poor dimensional stability and unclear boundaries of the microspheres, so the support effect and degradation effect are not ideal when applied to facial filling.

发明内容Summary of the invention

本发明提供了一种羟基磷灰石复合聚酯微球及其制备方法和应用,以解决现有技术中制备的羟基磷灰石微球尺寸稳定性差,微球的边界性不清晰,填充性和降解性差的问题。The invention provides a hydroxyapatite composite polyester microsphere and a preparation method and application thereof, so as to solve the problems that the hydroxyapatite microsphere prepared in the prior art has poor dimensional stability, unclear boundaries of the microsphere, and poor filling and degradability.

为解决上述发明目的,本发明提供的技术方案如下:In order to solve the above-mentioned invention object, the technical solution provided by the present invention is as follows:

一种羟基磷灰石复合聚酯微球,其原料按质量份计包括生物可吸收聚酯25~95份和羟基磷灰石5~18份。A hydroxyapatite composite polyester microsphere, the raw materials of which include 25-95 parts of bioabsorbable polyester and 5-18 parts of hydroxyapatite by weight.

优选地,所述羟基磷灰石复合聚酯微球的D50为6.1μm ~29.1μm。Preferably, the D50 of the hydroxyapatite composite polyester microspheres is 6.1 μm to 29.1 μm.

通常来讲可以通过微球的外观完整度和尺寸来判断微球的效果和临床表现。一般用于临床的聚酯微球的尺寸为20~60μm为最佳,既能起到占位刺激效果,又不会因过大提高囊肿风险。本发明的聚酯微球的D50为6.1μm ~29.1μm。Generally speaking, the effect and clinical manifestation of the microspheres can be judged by the appearance integrity and size of the microspheres. The size of polyester microspheres generally used in clinical practice is optimally 20 to 60 μm, which can both have a space-occupying stimulating effect and not increase the risk of cysts due to being too large. The D50 of the polyester microspheres of the present invention is 6.1 μm to 29.1 μm.

优选地,所述羟基磷灰石的粒径为20nm~45nm。Preferably, the particle size of the hydroxyapatite is 20 nm to 45 nm.

优选地,所述生物可吸收聚酯为聚乳酸、聚羟基乙酸、聚己内酯中的一种。Preferably, the bioabsorbable polyester is one of polylactic acid, polyglycolic acid and polycaprolactone.

一种基于前文所述的羟基磷灰石复合聚酯微球的制备方法,包括以下步骤;A method for preparing hydroxyapatite composite polyester microspheres based on the above-mentioned method comprises the following steps:

S1、将生物可吸收聚酯溶于有机溶剂中,得到质量-体积浓度为5%~20%的溶液1;S1, dissolving the bioabsorbable polyester in an organic solvent to obtain a solution 1 having a mass-volume concentration of 5% to 20%;

S2、将羟基磷灰石加入所述溶液1中,得到油相悬液,即溶液2;S2, adding hydroxyapatite to the solution 1 to obtain an oil phase suspension, i.e., solution 2;

S3、将乳化剂溶解后得到乳化水溶液,即溶液3;S3, dissolving the emulsifier to obtain an emulsified aqueous solution, i.e., solution 3;

S4、将溶液3的搅拌速度调整为400~1000rpm,同时以1000-3000mL/h的速度将溶液2滴入溶液3,得到乳化溶液;S4, adjusting the stirring speed of solution 3 to 400-1000 rpm, and simultaneously dropping solution 2 into solution 3 at a rate of 1000-3000 mL/h to obtain an emulsified solution;

本发明的制备方法中,通过溶液3液体转动的过程中产生的剪切力,将溶液2中的液体制成小球,在这个过程中,溶液3的搅拌速度和溶液2的滴加速度,以及溶液2和溶液3中相关溶质的体积浓度是获得合适尺寸微球的关键参数,只有在本发明的条件参数下,才能获得尺寸合格,外观清晰的羟基磷灰石复合聚酯微球。In the preparation method of the present invention, the liquid in solution 2 is made into small balls by the shear force generated during the rotation of solution 3. In this process, the stirring speed of solution 3 and the dripping speed of solution 2, as well as the volume concentration of relevant solutes in solution 2 and solution 3 are key parameters for obtaining microspheres of suitable sizes. Only under the conditions and parameters of the present invention can hydroxyapatite composite polyester microspheres with qualified sizes and clear appearance be obtained.

S5、乳化完成后,调整所述乳化溶液的搅拌速度为150-200rpm,降低温度为20~25℃,进行有机溶剂的挥发;S5. After the emulsification is completed, the stirring speed of the emulsified solution is adjusted to 150-200 rpm, and the temperature is reduced to 20-25° C. to volatilize the organic solvent;

S6、静置后得到沉淀物,将所述沉淀物清洗、干燥后得到羟基磷灰石复合聚酯微球。S6, after standing, a precipitate is obtained, and the precipitate is washed and dried to obtain hydroxyapatite composite polyester microspheres.

优选地,S1中所述有机溶剂为二氯甲烷、三氯甲烷、乙酸乙酯、二甲基亚砜、丙酮中的一种。Preferably, the organic solvent in S1 is one of dichloromethane, chloroform, ethyl acetate, dimethyl sulfoxide and acetone.

优选地,S3中所述溶液3中溶质的质量-体积浓度为2%~3%。Preferably, the mass-volume concentration of the solute in the solution 3 in S3 is 2% to 3%.

优选地,S3中所述乳化剂为聚乙烯吡咯烷酮、司班80、聚乙烯醇中的一种,S1中所述生物可吸收聚酯与S3中所述乳化剂的质量比为(5-19):(12-18)。Preferably, the emulsifier in S3 is one of polyvinyl pyrrolidone, Span 80 and polyvinyl alcohol, and the mass ratio of the bioabsorbable polyester in S1 to the emulsifier in S3 is (5-19): (12-18).

优选地,S6中所述干燥为真空干燥或冷冻干燥。Preferably, the drying in S6 is vacuum drying or freeze drying.

一种如前文所述的羟基磷灰石复合聚酯微球在制备面部填充去皱试剂中的应用。An application of the hydroxyapatite composite polyester microspheres as described above in the preparation of facial filling and anti-wrinkle agents.

微球类填充剂用于面部填充一般是前期利用占位作用改善面部皱纹,中后期靠聚乳酸微球刺激皮下组织生成胶原蛋白实现美容效果。但单一的聚乳酸微球经常出现尺寸不均一导致的过大的微球不易降解吸收,最终形成囊肿,造成局部发炎病变等严重后果。本发明中添加了羟基磷灰石作为附加成分,羟基磷灰石(Hydroxyapatite, HAP)是一种生物相容性好、生物活性强的无机材料,它是人体和动物骨骼的主要无机成分,在体内有一定的溶解度,并能参与体内的代谢过程。羟基磷灰石可以促进成人真皮成纤维细胞(hADF)增殖,注射后还能明显促进I型、III型胶原蛋白新生,提高真皮层胶原密度,因此在皮肤修复再生方面展现出了潜力。羟基磷灰石通过刺激胶原蛋白的再生,促进缺损组织的修复,显示出生物活性。此外,由于其具有良好的生物相容性和生物降解性,羟基磷灰石在体内可以逐渐被新生组织替代,最终降解为无害的钙盐和磷酸盐,无残留风险。羟基磷灰石成分的引入,可以增加微球整体的降解性能,使降解周期更为合理,降低纤维囊肿等并发症发生的概率。同时增加胶原蛋白的分泌,提高整体使用效果。Microsphere fillers are generally used for facial filling to improve facial wrinkles in the early stage by occupying the space, and in the middle and late stages, polylactic acid microspheres are used to stimulate subcutaneous tissue to produce collagen to achieve a cosmetic effect. However, single polylactic acid microspheres often have uneven sizes, resulting in oversized microspheres that are not easy to degrade and absorb, and eventually form cysts, causing serious consequences such as local inflammatory lesions. Hydroxyapatite is added as an additional component in the present invention. Hydroxyapatite (HAP) is an inorganic material with good biocompatibility and strong biological activity. It is the main inorganic component of human and animal bones, has a certain solubility in the body, and can participate in the metabolic process in the body. Hydroxyapatite can promote the proliferation of adult dermal fibroblasts (hADF), and after injection, it can also significantly promote the regeneration of type I and type III collagen, and increase the collagen density of the dermis, so it shows potential in skin repair and regeneration. Hydroxyapatite stimulates the regeneration of collagen and promotes the repair of defective tissue, showing biological activity. In addition, due to its good biocompatibility and biodegradability, hydroxyapatite can be gradually replaced by new tissue in the body and eventually degraded into harmless calcium salts and phosphates without residual risk. The introduction of hydroxyapatite components can increase the overall degradation performance of the microspheres, make the degradation cycle more reasonable, and reduce the probability of complications such as fibrocystic fibrosis. At the same time, it increases the secretion of collagen and improves the overall use effect.

上述技术方案,与现有技术相比至少具有如下有益效果:Compared with the prior art, the above technical solution has at least the following beneficial effects:

本发明中的羟基磷灰石复合聚酯微球由羟基磷灰石和可吸收聚酯组成,尺寸适宜,能够降低聚酯微球类产品在用于皮肤填充后发生炎症等不良症状的可能性,并使其功效更加稳定长效。本发明还提供一种羟基磷灰石复合聚酯微球的制备方法,严格控制各参数,将羟基磷灰石通过乳化法附着在聚酯微球上并使其均匀分布,从而得到一个合适的降解速率,提高微球刺激皮肤再生的活性,并且制备的微球尺寸合适,边界清晰,填充皮肤后支撑效果好。可将所制备的羟基磷灰石复合聚酯微球应用到面部填充去皱领域。The hydroxyapatite composite polyester microspheres of the present invention are composed of hydroxyapatite and absorbable polyester, and are of suitable size, which can reduce the possibility of adverse symptoms such as inflammation of polyester microsphere products after being used for skin filling, and make the efficacy more stable and long-lasting. The present invention also provides a preparation method of hydroxyapatite composite polyester microspheres, strictly controlling various parameters, attaching hydroxyapatite to polyester microspheres by emulsification and making them evenly distributed, thereby obtaining a suitable degradation rate, improving the activity of microspheres in stimulating skin regeneration, and the prepared microspheres are of suitable size, clear boundaries, and good supporting effect after filling the skin. The prepared hydroxyapatite composite polyester microspheres can be applied to the field of facial filling and wrinkle removal.

附图说明BRIEF DESCRIPTION OF THE DRAWINGS

图1为实施例1中制备的一种羟基磷灰石复合聚酯微球的显微结构图;FIG1 is a microstructure diagram of hydroxyapatite composite polyester microspheres prepared in Example 1;

图2为实施例2中制备的一种羟基磷灰石复合聚酯微球的显微结构图;FIG2 is a microstructure diagram of hydroxyapatite composite polyester microspheres prepared in Example 2;

图3为实施例3中制备的一种羟基磷灰石复合聚酯微球的显微结构图;FIG3 is a microstructure diagram of hydroxyapatite composite polyester microspheres prepared in Example 3;

图4为对比例1中制备的一种羟基磷灰石复合聚酯微球的显微结构图;FIG4 is a microstructure diagram of hydroxyapatite composite polyester microspheres prepared in Comparative Example 1;

图5为对比例2中制备的一种羟基磷灰石复合聚酯微球的显微结构图。FIG. 5 is a microscopic diagram of the hydroxyapatite composite polyester microspheres prepared in Comparative Example 2.

具体实施方式DETAILED DESCRIPTION

为使本发明实施例的目的、技术方案和优点更加清楚,下面将结合本发明实施例的附图,对本发明实施例的技术方案进行清楚、完整地描述。显然,所描述的实施例是本发明的一部分实施例,而不是全部的实施例。基于所描述的本发明的实施例,本领域普通技术人员在无需创造性劳动的前提下所获得的所有其他实施例,都属于本发明保护的范围。In order to make the purpose, technical solution and advantages of the embodiment of the present invention clearer, the technical solution of the embodiment of the present invention will be clearly and completely described below in conjunction with the drawings of the embodiment of the present invention. Obviously, the described embodiment is a part of the embodiment of the present invention, not all of the embodiments. Based on the described embodiment of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

实施例1Example 1

一种羟基磷灰石复合聚酯微球,其原料按质量份计包括生物可吸收聚酯95份和羟基磷灰石5份,所述羟基磷灰石的粒径为20nm。所述生物可吸收聚酯为聚羟基乙酸。A hydroxyapatite composite polyester microsphere, the raw materials of which include 95 parts of bioabsorbable polyester and 5 parts of hydroxyapatite by weight, the particle size of the hydroxyapatite is 20nm, and the bioabsorbable polyester is polyglycolic acid.

一种本实施例所述的羟基磷灰石复合聚酯微球的制备方法,包括以下步骤;A method for preparing hydroxyapatite composite polyester microspheres according to this embodiment comprises the following steps:

S1、称取95g聚羟基乙酸溶于乙酸乙酯中,磁力搅拌加速溶解,溶解时间为8小时,溶解完成后得到总体积为475mL的溶液,得到质量-体积浓度为20%的溶液1;S1, weigh 95g of polyglycolic acid and dissolve it in ethyl acetate, and stir magnetically to accelerate the dissolution. The dissolution time is 8 hours. After the dissolution is completed, a solution with a total volume of 475mL is obtained, and a solution 1 with a mass-volume concentration of 20% is obtained;

S2、将5g羟基磷灰石加入所述溶液1中,得到油相悬液,即溶液2;S2, adding 5 g of hydroxyapatite to the solution 1 to obtain an oil phase suspension, i.e., solution 2;

S3、称取60g聚乙烯吡咯烷酮,用纯水配置成总体积为3000mL的水溶液,开启搅拌及加热,加速溶解,溶解时间为6小时,得到乳化水溶液,即溶质的质量-体积浓度为2%的溶液3;S3, weigh 60g of polyvinyl pyrrolidone, and prepare it into an aqueous solution with a total volume of 3000mL with pure water, start stirring and heating to accelerate dissolution, and the dissolution time is 6 hours to obtain an emulsified aqueous solution, that is, a solution 3 with a mass-volume concentration of the solute of 2%;

S4、将溶液3的搅拌速度调整为600rpm,溶液2搅拌速度调整为200rpm,同时以1000mL/h的速度将溶液2滴入溶液3,得到乳化溶液;S4, adjusting the stirring speed of solution 3 to 600 rpm, adjusting the stirring speed of solution 2 to 200 rpm, and simultaneously dropping solution 2 into solution 3 at a rate of 1000 mL/h to obtain an emulsified solution;

S5、乳化完成后,调整所述乳化溶液的搅拌速度为200rpm,降低温度为25℃,进行有机溶剂的挥发,持续挥发16小时;S5. After the emulsification is completed, the stirring speed of the emulsified solution is adjusted to 200 rpm, the temperature is lowered to 25° C., and the organic solvent is volatilized for 16 hours;

S6、有机相挥发完全后,停止搅拌,静置10小时,待微球自然沉降后,弃上清液,采用纯水重悬并离心的方式对乳化产物进行清洗,离心机转速设为4000rpm,每次4分钟,清洗重复3次后更换无水乙醇清洗一次,采用离心分离收集弃掉上清液;S6. After the organic phase evaporates completely, stop stirring and let stand for 10 hours. After the microspheres settle naturally, discard the supernatant, resuspend in pure water and wash the emulsified product by centrifugation. The centrifuge speed is set to 4000 rpm for 4 minutes each time. After washing 3 times, replace with anhydrous ethanol for washing once, collect and discard the supernatant by centrifugation;

S7、将清洗后的干燥,得到羟基磷灰石复合聚酯微球,这里所述干燥的方式可以为真空干燥或冷冻干燥,较适宜的干燥参数为;冷冻干燥的温度为-120℃~-80℃,真空度为1~100Pa;真空干燥的温度为30℃~60℃,真空度为1~100Pa,本实施例中采用真空干燥的方式对清洗后的微球进行干燥,设置真空度不超过30Pa,温度45℃,干燥4h。S7. Dry the washed microspheres to obtain hydroxyapatite composite polyester microspheres. The drying method described here can be vacuum drying or freeze drying. The more suitable drying parameters are: the freeze drying temperature is -120°C~-80°C, and the vacuum degree is 1~100Pa; the vacuum drying temperature is 30°C~60°C, and the vacuum degree is 1~100Pa. In this embodiment, vacuum drying is used to dry the washed microspheres, and the vacuum degree is set not to exceed 30Pa, the temperature is 45°C, and the drying is carried out for 4h.

本实施例中制备的羟基磷灰石复合聚酯微球的显微结构图如图1所示。The microstructure of the hydroxyapatite composite polyester microspheres prepared in this example is shown in FIG1 .

以本实施例的羟基磷灰石复合聚酯微球为主要原料制备用于面部填充去皱的试剂。The hydroxyapatite composite polyester microspheres of this example are used as the main raw material to prepare the agent for facial filling and wrinkle removal.

实施例2Example 2

一种羟基磷灰石复合聚酯微球,其原料按质量份计包括生物可吸收聚酯25g和羟基磷灰石16.7g,所述羟基磷灰石的粒径为30nm。所述生物可吸收聚酯为聚己内酯。A hydroxyapatite composite polyester microsphere, the raw materials of which include 25g of bioabsorbable polyester and 16.7g of hydroxyapatite by weight, the particle size of the hydroxyapatite is 30nm, and the bioabsorbable polyester is polycaprolactone.

一种基于前文所述的羟基磷灰石复合聚酯微球的制备方法,包括以下步骤;A method for preparing hydroxyapatite composite polyester microspheres based on the above-mentioned method comprises the following steps:

S1、称取25g聚己内酯溶于丙酮中,磁力搅拌加速溶解,溶解时间为8小时,溶解完成后得到总体积为500mL的溶液,得到质量-体积浓度为5%的溶液1;S1, weigh 25g of polycaprolactone and dissolve it in acetone, and stir it with magnetic stirring to accelerate the dissolution. The dissolution time is 8 hours. After the dissolution is completed, a solution with a total volume of 500mL is obtained, and a solution 1 with a mass-volume concentration of 5% is obtained;

S2、将16.7g羟基磷灰石加入所述溶液1中,得到油相悬液,即溶液2;S2, adding 16.7 g of hydroxyapatite to the solution 1 to obtain an oil phase suspension, i.e., solution 2;

S3、称取75g司班80,用纯水配置成总体积为3000mL的水溶液,开启搅拌及加热,加速溶解,溶解时间为8小时,得到乳化水溶液,即溶质的质量-体积浓度为2.5%的溶液3;S3, weigh 75g of Span 80, and prepare it into an aqueous solution with a total volume of 3000mL with pure water, start stirring and heating to accelerate dissolution, and the dissolution time is 8 hours to obtain an emulsified aqueous solution, that is, a solution 3 with a mass-volume concentration of the solute of 2.5%;

S4、将溶液3的搅拌速度调整为1000rpm,溶液2搅拌速度调整为600rpm,同时以3000mL/h的速度将溶液2滴入溶液3,得到乳化溶液;S4, adjusting the stirring speed of solution 3 to 1000 rpm, adjusting the stirring speed of solution 2 to 600 rpm, and simultaneously dropping solution 2 into solution 3 at a rate of 3000 mL/h to obtain an emulsified solution;

S5、乳化完成后,调整所述乳化溶液的搅拌速度为150rpm,降低温度为20℃,进行有机溶剂的挥发;S5. After the emulsification is completed, the stirring speed of the emulsified solution is adjusted to 150 rpm, the temperature is lowered to 20° C., and the organic solvent is volatilized;

S6、有机相挥发完全后,停止搅拌,静置10小时,待微球自然沉降后,弃上清液,采用纯水重悬并离心的方式对乳化产物进行清洗,离心机转速设为4000rpm,每次5分钟,清洗重复5次后更换无水乙醇清洗一次,采用离心分离收集弃掉上清液;S6. After the organic phase evaporates completely, stop stirring and let stand for 10 hours. After the microspheres settle naturally, discard the supernatant, resuspend in pure water and wash the emulsified product by centrifugation. The centrifuge speed is set to 4000 rpm for 5 minutes each time. After washing is repeated 5 times, replace with anhydrous ethanol for washing once, collect by centrifugation and discard the supernatant;

S7、采用冷冻干燥的方式对清洗后的微球进行干燥,设置真空度不超过5Pa,冷阱温度-100℃,干燥12h,得到羟基磷灰石复合聚酯微球。S7. The cleaned microspheres are dried by freeze drying, the vacuum degree is set not more than 5 Pa, the cold trap temperature is -100°C, and the drying is performed for 12 hours to obtain hydroxyapatite composite polyester microspheres.

本实施例中制备的羟基磷灰石复合聚酯微球的显微结构图如图2所示。The microstructure of the hydroxyapatite composite polyester microspheres prepared in this example is shown in FIG2 .

以本实施例的羟基磷灰石复合聚酯微球为主要原料制备用于面部填充去皱的试剂。The hydroxyapatite composite polyester microspheres of this example are used as the main raw material to prepare the agent for facial filling and wrinkle removal.

实施例3Example 3

一种羟基磷灰石复合聚酯微球,其原料按质量份计包括生物可吸收聚酯62.5份和羟基磷灰石18份,所述羟基磷灰石的粒径为45nm。所述生物可吸收聚酯为聚乳酸。A hydroxyapatite composite polyester microsphere, the raw materials of which include 62.5 parts of bioabsorbable polyester and 18 parts of hydroxyapatite by weight, the particle size of the hydroxyapatite is 45nm, and the bioabsorbable polyester is polylactic acid.

一种基于前文所述的羟基磷灰石复合聚酯微球的制备方法,包括以下步骤;A method for preparing hydroxyapatite composite polyester microspheres based on the above-mentioned method comprises the following steps:

S1、称取62.5g聚乳酸溶于二氯甲烷中,磁力搅拌加速溶解,溶解时间为8小时,溶解完成后得到总体积为500mL的溶液,得到质量-体积浓度为12.5%的溶液1;S1, weigh 62.5g of polylactic acid and dissolve it in dichloromethane, and stir it with magnetic stirring to accelerate the dissolution. The dissolution time is 8 hours. After the dissolution is completed, a solution with a total volume of 500mL is obtained, and a solution 1 with a mass-volume concentration of 12.5% is obtained;

S2、将18g羟基磷灰石加入所述溶液1中,充分分散2小时以上,得到油相悬液,即溶液2;S2, adding 18 g of hydroxyapatite to the solution 1 and fully dispersing for more than 2 hours to obtain an oil phase suspension, i.e., solution 2;

S3、将90g聚乙烯醇用纯水配置成总体积为3000mL的水溶液,开启搅拌及加热,加速溶解,溶解时间为8小时,得到乳化水溶液,即溶质的质量-体积浓度为3%的溶液3;S3, 90g of polyvinyl alcohol was prepared into an aqueous solution with a total volume of 3000mL with pure water, stirring and heating were started to accelerate dissolution, and the dissolution time was 8 hours to obtain an emulsified aqueous solution, i.e., a solution 3 with a mass-volume concentration of the solute of 3%;

S4、将溶液3的搅拌速度调整为400rpm,溶液2搅拌速度调整为300rpm,同时以2700mL/h的速度将溶液2滴入溶液3,得到乳化溶液;S4, adjusting the stirring speed of solution 3 to 400 rpm, adjusting the stirring speed of solution 2 to 300 rpm, and simultaneously dropping solution 2 into solution 3 at a rate of 2700 mL/h to obtain an emulsified solution;

S5、乳化完成后,调整所述乳化溶液的搅拌速度为200rpm,降低温度为24℃,进行有机溶剂的挥发,持续挥发36小时;S5. After the emulsification is completed, the stirring speed of the emulsified solution is adjusted to 200 rpm, the temperature is lowered to 24° C., and the organic solvent is volatilized for 36 hours;

S6、有机相挥发完全后,停止搅拌,静置10小时,待微球自然沉降后,弃上清液,采用纯水重悬并离心的方式对乳化产物进行清洗,离心机转速设为3500rpm,每次5分钟,清洗重复5次后更换无水乙醇清洗一次,采用离心分离收集弃掉上清液;S6. After the organic phase evaporates completely, stop stirring and let stand for 10 hours. After the microspheres settle naturally, discard the supernatant, resuspend in pure water and wash the emulsified product by centrifugation. The centrifuge speed is set to 3500 rpm, 5 minutes each time, and the washing is repeated 5 times, and then the anhydrous ethanol is replaced for washing once. The supernatant is collected by centrifugation and discarded;

S7、采用真空干燥的方式对清洗后的微球进行干燥,设置真空度不超过30Pa,温度45℃,干燥4h,得到羟基磷灰石复合聚酯微球。S7. Dry the cleaned microspheres by vacuum drying, set the vacuum degree not exceeding 30 Pa, the temperature to 45° C., and dry for 4 hours to obtain hydroxyapatite composite polyester microspheres.

本实施例中制备的羟基磷灰石复合聚酯微球的显微结构图如图3所示。The microstructure of the hydroxyapatite composite polyester microspheres prepared in this example is shown in FIG3 .

以本实施例的羟基磷灰石复合聚酯微球为主要原料制备用于面部填充去皱的试剂。The hydroxyapatite composite polyester microspheres of this example are used as the main raw material to prepare the agent for facial filling and wrinkle removal.

将实施例3中的二氯甲烷替换为二甲基亚砜或三氯甲烷,制备得微球与实施例3中的相似。The dichloromethane in Example 3 is replaced by dimethyl sulfoxide or chloroform to prepare microspheres similar to those in Example 3.

对比例1Comparative Example 1

本对比例与实施例1相似,区别在于,本对比例中的制备方法中聚羟基乙酸为50g,羟基磷灰石为50g,对应得到的羟基磷灰石复合聚酯微球的原料按质量份计包括生物可吸收聚酯50份和羟基磷灰石50份。This comparative example is similar to Example 1, except that in the preparation method of this comparative example, the amount of polyglycolic acid is 50 g, the amount of hydroxyapatite is 50 g, and the raw materials of the corresponding hydroxyapatite composite polyester microspheres include 50 parts of bioabsorbable polyester and 50 parts of hydroxyapatite in parts by mass.

本对比例1中制备的羟基磷灰石复合聚酯微球的显微结构图如图4所示。The microstructure of the hydroxyapatite composite polyester microspheres prepared in Comparative Example 1 is shown in FIG. 4 .

实施例1-3与对比例1中制备的羟基磷灰石复合聚酯微球的粒径分布情况如表1;The particle size distribution of the hydroxyapatite composite polyester microspheres prepared in Examples 1-3 and Comparative Example 1 is shown in Table 1;

表1不同方式制备的羟基磷灰石复合聚酯微球的粒径分布情况Table 1 Particle size distribution of hydroxyapatite composite polyester microspheres prepared by different methods

可以看出实施例1-3中制备的羟基磷灰石复合聚酯微球形状规则,边界清晰。It can be seen that the hydroxyapatite composite polyester microspheres prepared in Examples 1-3 have regular shapes and clear boundaries.

对比例2Comparative Example 2

本对比例与实施例1相似,区别在于,本对比例中,S3中加入120g聚乙烯吡咯烷酮。本对比例中在制备的微球的显微结构如图5,可以看出制备的微球粒径过小。This comparative example is similar to Example 1, except that in this comparative example, 120 g of polyvinyl pyrrolidone is added to S3. The microstructure of the microspheres prepared in this comparative example is shown in FIG5 , and it can be seen that the particle size of the prepared microspheres is too small.

以上,仅为本发明的具体实施方式,但本发明的保护范围并不局限于此,本发明的保护范围应以权利要求的保护范围为准。The above are only specific embodiments of the present invention, but the protection scope of the present invention is not limited thereto. The protection scope of the present invention shall be based on the protection scope of the claims.

Claims (10)

1.一种羟基磷灰石复合聚酯微球,其特征在于,其原料按质量份计包括生物可吸收聚酯25~95份和羟基磷灰石5~18份。1. A hydroxyapatite composite polyester microsphere, characterized in that the raw materials thereof include 25 to 95 parts by mass of bioabsorbable polyester and 5 to 18 parts by mass of hydroxyapatite. 2.根据权利要求1所述的一种羟基磷灰石复合聚酯微球,其特征在于,所述羟基磷灰石复合聚酯微球的D50为6.1μm ~29.1μm。2. The hydroxyapatite composite polyester microsphere according to claim 1, characterized in that the D50 of the hydroxyapatite composite polyester microsphere is 6.1 μm ~ 29.1 μm. 3.根据权利要求1所述的一种羟基磷灰石复合聚酯微球,其特征在于,所述羟基磷灰石的粒径为20nm~45nm。3. The hydroxyapatite composite polyester microsphere according to claim 1, wherein the particle size of the hydroxyapatite is 20 nm to 45 nm. 4.根据权利要求1所述的一种羟基磷灰石复合聚酯微球,其特征在于,所述生物可吸收聚酯为聚乳酸、聚羟基乙酸、聚己内酯中的一种。4 . The hydroxyapatite composite polyester microsphere according to claim 1 , wherein the bioabsorbable polyester is one of polylactic acid, polyglycolic acid, and polycaprolactone. 5.一种基于权利要求1-4中任意一项所述的羟基磷灰石复合聚酯微球的制备方法,其特征在于,包括以下步骤;5. A method for preparing hydroxyapatite composite polyester microspheres according to any one of claims 1 to 4, characterized in that it comprises the following steps; S1、将生物可吸收聚酯溶于有机溶剂中,得到质量-体积浓度为5%~20%的溶液1;S1, dissolving the bioabsorbable polyester in an organic solvent to obtain a solution 1 having a mass-volume concentration of 5% to 20%; S2、将羟基磷灰石加入所述溶液1中,得到油相悬液,即溶液2;S2, adding hydroxyapatite to the solution 1 to obtain an oil phase suspension, i.e., solution 2; S3、将乳化剂溶解后得到乳化水溶液,即溶液3;S3, dissolving the emulsifier to obtain an emulsified aqueous solution, i.e., solution 3; S4、将溶液3的搅拌速度调整为400~1000rpm,同时以1000-3000mL/h的速度将溶液2滴入溶液3,得到乳化溶液;S4, adjusting the stirring speed of solution 3 to 400-1000 rpm, and simultaneously dropping solution 2 into solution 3 at a rate of 1000-3000 mL/h to obtain an emulsified solution; S5、乳化完成后,调整所述乳化溶液的搅拌速度为150-200rpm,降低温度至20~25℃,进行有机溶剂的挥发;S5. After the emulsification is completed, the stirring speed of the emulsified solution is adjusted to 150-200 rpm, and the temperature is lowered to 20-25° C. to volatilize the organic solvent; S6、静置后得到沉淀物,将所述沉淀物清洗、干燥后得到羟基磷灰石复合聚酯微球。S6, after standing, a precipitate is obtained, and the precipitate is washed and dried to obtain hydroxyapatite composite polyester microspheres. 6.根据权利要求5所述的方法,其特征在于,S1中所述有机溶剂为二氯甲烷、三氯甲烷、乙酸乙酯、二甲基亚砜、丙酮中的一种。6. The method according to claim 5, characterized in that the organic solvent in S1 is one of dichloromethane, chloroform, ethyl acetate, dimethyl sulfoxide, and acetone. 7.根据权利要求5所述的方法,其特征在于,S3中所述溶液3中溶质的质量-体积浓度为2%~3%。7. The method according to claim 5, characterized in that the mass-volume concentration of the solute in the solution 3 in S3 is 2% to 3%. 8.根据权利要求5所述的方法,其特征在于,S3中所述乳化剂为聚乙烯吡咯烷酮、司班80、聚乙烯醇中的一种,S1中所述生物可吸收聚酯与S3中所述乳化剂的质量比为(5-19):(12-18)。8. The method according to claim 5, characterized in that the emulsifier in S3 is one of polyvinyl pyrrolidone, Span 80, and polyvinyl alcohol, and the mass ratio of the bioabsorbable polyester in S1 to the emulsifier in S3 is (5-19): (12-18). 9.根据权利要求5所述的方法,其特征在于,S6中所述干燥为真空干燥或冷冻干燥。9. The method according to claim 5, characterized in that the drying in S6 is vacuum drying or freeze drying. 10.一种如权利要求1-4任一所述的羟基磷灰石复合聚酯微球在制备面部填充去皱试剂中的应用。10. Use of the hydroxyapatite composite polyester microspheres according to any one of claims 1 to 4 in the preparation of facial filling and anti-wrinkle agents.
CN202411221975.7A 2024-09-02 2024-09-02 Hydroxyapatite composite polyester microsphere and preparation method and application thereof Pending CN118903564A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411221975.7A CN118903564A (en) 2024-09-02 2024-09-02 Hydroxyapatite composite polyester microsphere and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202411221975.7A CN118903564A (en) 2024-09-02 2024-09-02 Hydroxyapatite composite polyester microsphere and preparation method and application thereof

Publications (1)

Publication Number Publication Date
CN118903564A true CN118903564A (en) 2024-11-08

Family

ID=93296040

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202411221975.7A Pending CN118903564A (en) 2024-09-02 2024-09-02 Hydroxyapatite composite polyester microsphere and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN118903564A (en)

Similar Documents

Publication Publication Date Title
US11998638B2 (en) Microparticles comprising PCL and uses thereof
CN111298196A (en) Polylactic acid porous microsphere, preparation method and application thereof
JP2000516839A (en) Subcutaneous or intradermal implants
CN114949359B (en) Acellular matrix particle filler and preparation method thereof
CN111632203A (en) A kind of multifunctional supramolecular hydrogel for preventing postoperative tissue adhesion and preparation method
CN113117142B (en) Biodegradable injection filler, preparation method and application thereof
CN104587526A (en) Collagen-hydroxyapatite nerve scaffold and preparation method thereof
CN118903564A (en) Hydroxyapatite composite polyester microsphere and preparation method and application thereof
CN118320184A (en) Injectable exosome-loaded silk fibroin microsphere-carboxymethyl cellulose composite gel and preparation method and application thereof
CN109010922A (en) Bone Defect Repari nano fibrous membrane and preparation method thereof
KR20190093188A (en) Method for producing suspension form of pulverized decellularized extracellular matrix
CN107096065A (en) Composite nano-fiber membrane containing polysialic acids and preparation method and application
US20240285828A1 (en) Composition using fibrotic acellular dermal matrix, and method for preparing same
CN116333378A (en) Polyhydroxyalkanoate microsphere composite gel and preparation method and application thereof
JP2023515762A (en) tissue engineering scaffold
CN116271224B (en) A soft tissue regeneration filler and preparation method thereof
CN116370706B (en) A regenerated silk fibroin solid microsphere scaffold and an injectable soft tissue regeneration filler
CN113209370B (en) Biodegradable injection filler, preparation method and application thereof
CN115887760A (en) A preparation process of L-polylactic acid for injection
Chang et al. Engineered collagen/PLLA composite fillers to induce rapid and long-term collagen regeneration
CN119775388A (en) Regenerative human type I collagen, medical material and preparation method thereof
CN118903551A (en) Modularized preparation method of sodium hyaluronate composite gel loaded with degradable microspheres for injection
CN118161658A (en) Preparation method and application of microsphere gel material
IT201900013311A1 (en) NEW TISSUE FILLING COMPOSITION

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination